文献速递心脏核医学骨显像与常规 SPECT

遗传性转甲状腺素蛋白淀粉样变性患者骨显像中心肌[99mTc]Tc-羟基二膦酸盐摄取:早期随访标志物?

Cardiac [99mTc]Tc-hydroxydiphosphonate uptake on bone scintigraphy in patients with hereditary transthyretin amyloidosis: an early follow-up marker?
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-10-16

回顾性队列研究比较20例接受TTR基因沉默剂patisiran治疗与12例接受TTR稳定剂治疗的ATTRv淀粉样变性患者,骨显像心脏/全身比值在patisiran组从4.84降至4.16(p<.001),在TTR稳定剂组从4.46升至4.96(p=.010),提示心脏示踪剂摄取变化可能是治疗特异性反应或疾病进展的早期标志物。

要点

  • patisiran组心脏/全身比值中位数从4.84降至4.16(p<.001),治疗29[15-34]个月。
  • TTR稳定剂组心脏/全身比值从4.46升至4.96(p=.010),治疗24[20-30]个月。
  • TTR稳定剂组肌钙蛋白T从19.5[9.3-34.0]ng/L升至20.0[11.8-47.8]ng/L(p=.025)。

核心结论

  • 骨显像中心脏示踪剂摄取变化可能是ATTRv淀粉样变性患者治疗特异性反应或疾病进展的早期标志物。

研究设计与样本

  • 回顾性队列研究,比较20例接受TTR基因沉默剂patisiran治疗与12例接受TTR稳定剂治疗的ATTRv淀粉样变性患者。

主要发现

  • patisiran组治疗29[15-34]个月后心脏/全身比值中位数从4.84[4.00-5.31]降至4.16[3.66-4.81](p<.001),其他随访参数无变化。
  • TTR稳定剂组治疗24[20-30]个月后心脏/全身比值从4.46[3.24-5.13]升至4.96[3.39-5.80](p=.010),肌钙蛋白T从19.5[9.3-34.0]ng/L升至20.0[11.8-47.8]ng/L(p=.025),其余参数无变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There is a need for early quantitative markers of potential treatment response in patients with hereditary transthyretin (ATTRv) amyloidosis to guide therapy. This study aims to evaluate changes in cardiac tracer uptake on bone scintigraphy in ATTRv amyloidosis patients on different treatments. METHODS: In this retrospective cohort study, outcomes of 20 patients treated with the transthyretin (TTR) gene silencer patisiran were compared to 12 patients treated with a TTR-stabilizer. Changes in NYHA class, cardiac biomarkers in serum, wall thickness, and diastolic parameters on echocardiography and NYHA class during treatment were evaluated. RESULTS: Median heart/whole-body (H/WB) ratio on bone scintigraphy decreased from 4.84 [4.00 to 5.31] to 4.16 [3.66 to 4.81] (p < .001) in patients treated with patisiran for 29 [15-34] months. No changes in the other follow-up parameters were observed. In patients treated with a TTR-stabilizer for 24 [20 to 30] months, H/WB ratio increased from 4.46 [3.24 to 5.13] to 4.96 [ 3.39 to 5.80] (p = .010), and troponin T increased from 19.5 [9.3 to 34.0] ng/L to 20.0 [11.8 to 47.8] ng/L (p = .025). All other parameters did not change during treatment with a TTR-stabilizer. CONCLUSION: A change in cardiac tracer uptake on bone scintigraphy may be an early marker of treatment-specific response or disease progression in ATTRv amyloidosis patients.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Tingen HSA, Tubben A, Bijzet J, et al. Cardiac [99mTc]Tc-hydroxydiphosphonate uptake on bone scintigraphy in patients with hereditary transthyretin amyloidosis: an early follow-up marker? Eur J Nucl Med Mol Imaging. 2023. PMID: 37843599. doi:10.1007/s00259-023-06459-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。